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Abstract
Background: Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign
prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have show
effectiveness with lower doses. The objective of the current study was to determine in men with
benign prostatic hyperplasia, previously treated for at least one year with finasteride 5 mg daily, if
they will maintain subjective and objective improvements in urinary obstruction when treated with
2.5 mg of finasteride daily for one year.
Methods: In an open label, prospective study, 40 men with benign prostatic hyperplasia, previously
treated for at least one year with 5 mg of finasteride, took 2.5 mg of finasteride daily for one year.
Measurements included AUA symptom score, maximum flow rate, voided volume and PSA.
Results: There were no significant changes in maximum flow rate, voided volume, or AUA
symptom score after one year of finasteride 2.5 mg daily therapy. PSA increased significantly, p <
.01, after one year of finasteride 2.5 mg daily, 2.0 +1.4 ng/ml, when compared to finasteride 5 mg
daily, 1.4+ 1.0 ng/ml.
Conclusions: The daily dose of finasteride can be reduced to 2.5 mg daily without significant effect
on subjective and objective measures of urinary obstruction. Although statistically significant
increases in PSA are noted when reducing the daily finasteride dose from 5 mg to 2.5 mg, the clinical
significance of a mean .6 ng/ml increase in PSA is questionable.
Introduction
Finasteride is a synthetic inhibitor of human 5 alpha re-
ductase, an enzyme that converts testosterone to dihy-
drotestosterone (DHT) within the prostate (1). Placebo-
controlled studies have demonstrated improvements in
subjective and objective measurements of urinary outlet
obstruction in men with benign prostatic hyperplasia
treated with finasteride 5 mg daily for one year (2). Com-
parable reductions in DHT levels noted with 5 mg of fin-
asteride have been observed with dosages as low as 1.5 mg
(3,4). Given the current monthly cost of $63 for 5 mg dai-
ly finasteride and the anticipated lifetime requirement for
therapy, a less costly maintenance regimen, which is able
to control symptoms, would be beneficial.
The current study was undertaken to determine in men
with benign prostatic hyperplasia previously treated with
finasteride 5 mg daily for at least one year, if 2.5 mg of fi-
nasteride daily for an additional year will maintain sub-
jective and objective improvements in urinary
obstruction.
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Patients and Methods
This was an open label, prospective study involving 40
men with a history of benign prostatic hyperplasia treated
for at least one year with 5 mg of finasteride daily. All sub-
jects reported subjective improvement in urinary symp-
toms with the 5 mg finasteride dose. The study was
approved by the institutional review board at Mercy Hos-
pital, San Diego, CA, and all men gave written informed
consent.
On day 1 and after one year of therapy with finasteride 2.5
mg a day, subjects completed an American Urological As-
sociation Symptom Index form and Quality of Life ques-
tionnaire (5), blood was drawn for prostate-specific
antigen (PSA), and maximal urinary flow rate and voided
volume were determined using a calibrated Dantec uri-
nary flowmeter. The subjects were given a pill cutter and
instructed to cut a 5 mg finasteride tablet in half in order
to take 2.5 mg daily. Serum PSA was measured using a
Hybritech, immunoradiometric assay.
Mean, standard deviation and paired T tests were per-
formed on the day 1 and one year data using Statgraphics
Plus statistical software. All tests of significance were two-
tailed, and all P values of < .05 were considered to indicate
significance.
Results
Urodynamic, AUA symptom and quality of life scores,
and PSA values on day 1 and one year after 2.5 mg of fin-
asteride daily are presented in Table 1. There was no sig-
nificant change in any urodynamic measurement or AUA
symptom and quality of life score after one year of finas-
teride 2.5 mg a day. There was a statistically significant (p
<.01) increase in PSA, mean .6 ng/ml, observed after one
year of finasteride at 2.5 mg a day.
Discussion
The current study has demonstrated, in a select group of
men with benign prostatic hyperplasia and symptomatic
improvement after treatment with 5 mg a day of finas-
teride, the dose can be reduced to 2.5 mg daily without
significant change in urodynamic measurements of ob-
struction or worsening of symptoms. The dose of 2.5 mg
was selected for the current study because of the relative
ease in splitting a 5 mg tablet, but significant improve-
ments in urodynamic measurements and obstructive
symptoms have been demonstrated with a 1 mg a day
dose (2). The current price of the 1 mg finasteride
($46.88/mo), approved for alopecia, is more than the cost
of splitting a 5 mg tablet in order to obtain the 2.5 mg
dose ($31.50/mo) and the efficacy of reducing the finas-
teride maintenance dose from 5 mg daily to 1 mg daily
has not been investigated.
Gormley, et. al., has reported no significant difference in
PSA values at one year for men treated with 1 mg or 5 mg
finasteride daily (2). There are no published reports on
the effect of finasteride on PSA values for treatment peri-
ods greater than one year. The significant increase in PSA,
noted after one year of finasteride at 2.5 mg daily in the
present study, is of questionable clinical importance given
a mean increase of only .6 ng/ml. However, this may rep-
resent a regrowth of prostatic tissue, which may affect uro-
dynamic measurements and symptom scores beyond the
one year observation period utilized in this study. When
utilizing the PSA for prostate cancer detection in a patient
receiving finasteride, it is prudent to recheck the PSA 3–6
months after any finasteride adjustments, in order to de-
termine a new baseline for future reference.
The clinical benefits of 5 mg of finasteride with respect to
symptom scores, peak urinary flow rates, and prostatic
volumes appears to reach a maximum after 6 months of
Table 1: Mean and standard deviation for maximal flow rate, total voided volume, PSA, AUA score on day 1 and one year after 2.5 mg 
of finasteride daily.
Day 1 1 Year
Maximal flow rate cc/sec n = 38 13.7 ± 5.4 13.6 ± 6.4
Voided Volume 283 cc n = 38 283 ± 93 282 ± 98
PSA ng/ml n = 28 1.4 ± 1.0 2.0 ± 1.4*
AUA score
Part A Urinary symptoms n = 40 9.6 ± 5.9 9.3 ± 5.0
Part B Problems due to symptoms n = 
39
6.4 ± 5.5 6.1 ± 4.3
Part C Quality of life due to urinary 
problems n = 39
4.2 ± 3.2 4.5 ± 3.3
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daily therapy (2). Results from the current study would
suggest, in those patients with improvement in prostatic
symptoms after receiving 5 mg of finasteride daily for 6
months the dose can safely be reduced to 2.5 mg daily.
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